Hopec Pharma

About Hopec Pharma

Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli to target and eliminate non-muscle-invasive bladder cancer cells. This approach addresses the need for more effective and patient-friendly treatment options in bladder cancer care.

```xml <problem> Non-muscle-invasive bladder cancer (NMIBC) requires more effective and patient-friendly treatment options. Current treatments often have limited efficacy or significant side effects, creating a need for innovative therapeutic approaches. </problem> <solution> Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli (E. coli) to selectively target and eliminate NMIBC cells. This innovative approach aims to improve treatment outcomes while enhancing patient comfort. By leveraging cutting-edge science and strategic global partnerships, Hopec Pharma seeks to deliver therapies that surpass existing options and redefine the future of bladder cancer care. UPEC-FimON represents a significant advancement in cancer therapy, offering a novel mechanism for targeting and eradicating bladder cancer cells. </solution> <features> - Genetically modified uropathogenic E. coli (UPEC) for targeted delivery to bladder cancer cells - Immunotherapy approach to stimulate the patient's immune system against cancer - Selective targeting of non-muscle-invasive bladder cancer cells - GMP-certified production through partnership with Scinai Immunotherapeutics - Phase 1 multicenter trials planned for Q2 2025 at Hadassah and Sheba medical centers - Research in immune mechanisms via single-cell RNA-seq studies </features> <target_audience> The primary target audience includes patients diagnosed with non-muscle-invasive bladder cancer and the healthcare providers who treat them, such as oncologists and urologists. </target_audience> ```

What does Hopec Pharma do?

Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli to target and eliminate non-muscle-invasive bladder cancer cells. This approach addresses the need for more effective and patient-friendly treatment options in bladder cancer care.

Where is Hopec Pharma located?

Hopec Pharma is based in גבעת שמואל, ישראל.

When was Hopec Pharma founded?

Hopec Pharma was founded in 2023.

Who founded Hopec Pharma?

Hopec Pharma was founded by Gadi Klarsfeld and Estee Rosen.

  • Gadi Klarsfeld - CEO/Co-Founder
  • Estee Rosen - Co-Founder/Chairwoman/COO
Location
גבעת שמואל, ישראל
Founded
2023
Employees
3 employees
Looking for specific startups?
Try our free semantic startup search

Hopec Pharma

Score: 40/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli to target and eliminate non-muscle-invasive bladder cancer cells. This approach addresses the need for more effective and patient-friendly treatment options in bladder cancer care.

hopec-pharma.com200+
Founded 2023 – גבעת שמואל, ישראל

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (<5)

Gadi Klarsfeld

CEO/Co-Founder

Estee Rosen

Co-Founder/Chairwoman/COO

Company Description

Problem

Non-muscle-invasive bladder cancer (NMIBC) requires more effective and patient-friendly treatment options. Current treatments often have limited efficacy or significant side effects, creating a need for innovative therapeutic approaches.

Solution

Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli (E. coli) to selectively target and eliminate NMIBC cells. This innovative approach aims to improve treatment outcomes while enhancing patient comfort. By leveraging cutting-edge science and strategic global partnerships, Hopec Pharma seeks to deliver therapies that surpass existing options and redefine the future of bladder cancer care. UPEC-FimON represents a significant advancement in cancer therapy, offering a novel mechanism for targeting and eradicating bladder cancer cells.

Features

Genetically modified uropathogenic E. coli (UPEC) for targeted delivery to bladder cancer cells

Immunotherapy approach to stimulate the patient's immune system against cancer

Selective targeting of non-muscle-invasive bladder cancer cells

GMP-certified production through partnership with Scinai Immunotherapeutics

Phase 1 multicenter trials planned for Q2 2025 at Hadassah and Sheba medical centers

Research in immune mechanisms via single-cell RNA-seq studies

Target Audience

The primary target audience includes patients diagnosed with non-muscle-invasive bladder cancer and the healthcare providers who treat them, such as oncologists and urologists.